Status:

COMPLETED

Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline

Lead Sponsor:

Mutual Pharmaceutical Company, Inc.

Conditions:

Pharmacokinetics

Eligibility:

MALE

18-45 years

Phase:

PHASE1

Brief Summary

In a prior in vitro study using human hepatocytes quinine was shown to induce the activity of Cytochrome p450 CYP 1A2. The present study will evaluate the extent to which quinine sulfate-related induc...

Detailed Description

This study will evaluate the effect of steady-state quinine sulfate on the pharmacokinetics of single dose theophylline and the effect of single dose theophylline on the pharmacokinetics of steady-sta...

Eligibility Criteria

Inclusion

  • Medically healthy non-smoking, non-obese (≥ 55kg and within 15% of ideal body weight) adult male volunteers 18-45 years of age

Exclusion

  • Subjects with history or presence of glucose 6 phosphate dehydrogenase deficiency, myasthenia gravis, optic neuritis, glaucoma or significant cardiovascular disease (including hypotension, bradycardia or EKG abnormalities), pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric disease or an active sexually transmitted disease
  • Subjects with significant blood loss in the prior 56 days, plasma donation within 7 days , hemoglobin \<12.0 g/dl or who have participated in another clinical trial within the prior 30 days
  • Subjects with recent (2-year) history or evidence of alcoholism or drug abuse
  • Subjects who have used any drugs or substances known to inhibit or induce cytochrome P450 (CYP) enzymes and/or P-glycoprotein within 30 days prior to the first dose and throughout the study
  • Subjects who test positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).
  • Subjects who are pregnant or lactating or have hypersensitivity to quinine sulfate, mefloquine, quinidine or hypersensitivity to theophylline or aminophylline.

Key Trial Info

Start Date :

August 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2007

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT00779259

Start Date

August 1 2007

End Date

September 1 2007

Last Update

October 28 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

PRACS Institute

Fargo, North Dakota, United States, 58104